Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Acitretin
Drug ID BADD_D00036
Description An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.
Indications and Usage For the treatment of severe psoriasis in adults.
Marketing Status approved
ATC Code D05BB02
DrugBank ID DB00459
KEGG ID D02754
MeSH ID D017255
PubChem ID 5284513
TTD Drug ID D05QDC
NDC Product Code 17337-0003; 59981-011; 0093-1136; 0115-1752; 42291-087; 62147-0145; 0115-1751; 42794-081; 0378-7020; 71214-0698; 42291-088; 58159-058; 71052-692; 0115-1753; 17337-0004; 71214-0667; 0115-1750; 71214-0668; 71214-0669; 42291-086; 42794-080; 0093-1135; 0093-1138; 62147-0146; 76055-0001; 42794-083; 0378-7023
UNII LCH760E9T7
Synonyms Acitretin | Etretin | Isoacitretin | Isoetretin | Ro 10-1670 | Ro 101670 | Ro-10-1670 | Ro101670 | 13-cis-Acitretin | Neotigason | Soriatane | Acitretin, (Z,E,E,E)-Isomer | Ro-13-7652 | Ro137652 | Ro 13-7652 | Ro 137652
Chemical Information
Molecular Formula C21H26O3
CAS Registry Number 55079-83-9
SMILES CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Photophobia17.17.02.006; 06.01.01.004--
Photosensitivity reaction23.03.09.0030.001250%
Platelet count decreased13.01.04.001--
Proctalgia07.03.02.001--
Protein total increased13.09.01.005--Not Available
Proteinuria20.02.01.011--
Pruritus23.03.12.0010.003124%
Psoriasis23.03.14.002; 10.02.01.0360.007123%Not Available
Psoriatic arthropathy10.02.01.031; 23.03.14.005; 15.01.10.0010.003749%Not Available
Pulmonary embolism24.01.06.001; 22.06.02.0010.001250%Not Available
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Pustular psoriasis23.03.14.006; 10.02.01.1020.002499%Not Available
Pyogenic granuloma24.03.06.002; 23.10.01.001; 16.26.01.001; 07.20.02.0040.001250%Not Available
Pyrexia08.05.02.003--
Rash23.03.13.0010.003999%Not Available
Rash erythematous23.03.13.029--Not Available
Rash macular23.03.13.003--Not Available
Red blood cell count decreased13.01.05.007--Not Available
Red blood cell count increased13.01.05.008--Not Available
Red blood cells urine positive13.13.02.003--Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.001250%
Reticulocyte count decreased13.01.05.009--Not Available
Reticulocyte count increased13.01.05.010--Not Available
Retinal haemorrhage24.07.05.003; 06.10.01.001--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Rickets15.02.03.006; 14.04.04.0050.001875%Not Available
Rosacea23.02.08.0010.001250%Not Available
Saliva altered07.06.01.004--Not Available
Salivary hypersecretion07.06.01.009--Not Available
Scab23.03.03.004--Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene